title: Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience.
authors: Department of Urology, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.
authors: H
authors: H
authors: Ichikura
authors: K
authors: K
authors: Tanabe
authors: T
authors: T
authors: Tokumoto
authors: T
authors: T
authors: Shimuzu
authors: N
authors: N
authors: Ishikawa
authors: M
authors: M
authors: Harano
authors: M
authors: M
authors: Inui
authors: M
authors: M
authors: Manu
authors: S
authors: S
authors: Ito
authors: H
authors: H
authors: Shimmura
authors: H
authors: H
authors: Okuda
authors: T
authors: T
authors: Yagisawa
authors: S
authors: S
authors: Fuchinoue
authors: H
authors: H
authors: Toma
mesh_terms: D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy; D006085:Graft Survival; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012189:Retrospective Studies; D012263:Ribonucleosides / Q000627:therapeutic use; D016559:Tacrolimus / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D006146:Guanidines; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D012263:Ribonucleosides; C010052:mizoribine; D016572:Cyclosporine; D001379:Azathioprine; C037258:gusperimus; D016559:Tacrolimus; D008775:Methylprednisolone